100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
15356-60-2Emtricitabine Impurity 10
● In Stock
| Catalogue No.: | VL54015 |
|---|---|
| CAS No.: | 15356-60-2 |
| Mol. Formula: | C10H20O |
| Mol. Weight: | 156.27 g/mol |
Additional information on CAS 15356-60-2
Parent drug
EmtricitabineIUPAC Name
(1S, 2R, 5S)-5-Methyl-2-(1-methylethyl)cyclohexanolSynonyms
(1S,2R,5S)-(+)-Menthol; (+)-Menthol; d-Menthol; (1S, 2R, 5S)-5-Methyl-2-(1-methylethyl)cyclohexanol; [1S-(1?, 2?, 5?)]-5-Methyl-2-(1-methylethyl)c;yclohexanol; (1S, 3S, 4R)-(+)-Menthol; (+)-Menthol; (1S, 2R, 5S)-(+)-Menthol; (1S, 2R, 5S)-Menthol; d-Menthol;Description
Also known as (1S,2R,5S)-(+)-Menthol, (+)-Menthol, (1S,2R,5S)-Menthol or d-Menthol is a nucleoside reverse transcriptase inhibitor (NRTI) in combination with other antiviral agents it shows activity against HIV. It is approved for use in combination therapy.References
‘Sax, Paul E., et al. “Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Dolutegravir with Emtricitabine and Tenofovir Alafenamide, for Initial Treatment of HIV-1 Infection (GS-US-380–1490): A Randomised, Double-Blind, Multicentre, Phase 3, Non-Inferiority Trial.†The Lancet, vol. 390, no. 10107, Nov. 2017, pp. 2073–82, https://doi.org/10.1016/s0140-6736(17)32340-1. Bang, Lynne M., and Lesley J. Scott. “Emtricitabine.†Drugs, vol. 63, no. 22, 2003, pp. 2413–24, https://doRequest a Quote
"*" indicates required fields
Other products related to Emtricitabine impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
